News
Lab updates
Snapshots from conferences, collaborations, and study milestones.
Media pickup: Bioengineer.org recaps ASTRO lymphocyte-sparing study
Bioengineer.org spotlights our analysis linking lymphocyte preservation to better outcomes—supporting dose and volume de-escalation for HPV-positive disease.
ASTROnews Winter 2025 feature on H&N biomarkers
ASTROnews publishes “Winter Is Coming: The Changing Landscape of Head & Neck Cancer Biomarkers” by N. Riaz & B. Chera—a reader-friendly overview of precision biomarkers.
Shu Yazaki publishes AlphaMissense DDR study
Postdoctoral fellow Shu Yazaki reports in JCO Precision Oncology on using AlphaMissense to classify DDR-associated mutations across cancer cohorts.
Phase III trial 24-200 (NCT06563479) opens with Riaz as co-investigator
MSK launches a personalized 3-week chemoradiation protocol (FMISO-selected) versus standard 7-week CRT for HPV-positive OPC, listing Dr. Riaz as co-investigator.
Phase II trial 25-040 (NCT06984861) launches
MSK opens trial 25-040: reduced-dose (30 Gy/3 weeks) CRT with adaptive escalation based on early response, listing Dr. Riaz as co-investigator.